search
Back to results

Aortic Arch Related Cerebral Hazard Trial (ARCH) (ARCH)

Primary Purpose

Brain Infarction, Transient Ischemic Attack, Embolism

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Warfarin
Clopidogrel-aspirin
Sponsored by
Assistance Publique - Hôpitaux de Paris
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Brain Infarction focused on measuring TIA/Brain infarct, and plaque>4mm in the aortic arch, Or peripheral embolism, and plaque>4 mm in the thoracic aorta

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patients of both sexes aged ≥ 18 years with the following 4 inclusion criteria: One of the 3 following ischemic events in the preceding 6 months: Transient ischemic attack (TIA) Non-disabling brain infarcts: Inclusion within 6 months after onset Duration of symptoms and signs greater than 24 hours Neurological signs at the time of randomization with a Rankin Scale grade 3 or less With normal computed tomography (CT) scan or CT scan showing a brain infarct (even hemorrhagic infarct) Peripheral embolism Atherosclerotic plaque in the thoracic aorta is defined as wall thickness ≥ 4 mm where the protruding material is the largest, measured at transesophageal echocardiography with multiplane transducer or a plaque less than 4 mm but with mobile component. Informed consent signed Life expectancy > 3 years Exclusion Criteria: Other causes of embolism: Cardiac: endocarditis, atrial fibrillation, intra-cardiac thrombus, valvular prosthesis, rheumatic valvulopathy, left ventricular aneurysm, or ejection fraction less than 25% Atherosclerotic stenosis ipsilateral to the embolic territory: internal carotid artery stenosis greater than 70%, or severe (judgment of the investigator) intracranial stenosis, or scheduled carotid endarterectomy (in that case inclusion is possible 30 days after the procedure) Uncommon causes: dissection, vasculitis, procoagulant state, or sickle cell disease Other exclusion criteria: Intercurrent illness with life expectancy less than 36 months Pregnancy and non-menopausal women Unwillingness to participate Poor medication compliance expected Toxicomania Absolute indication for anticoagulant therapy (e.g. atrial fibrillation, intracardiac thrombus, prosthetic valve) Scheduled for carotid endarterectomy (randomization is possible 30 days after endarterectomy) CT scan with an intracranial lesion other than brain infarction (space occupying mass, intracranial hemorrhage) Transesophageal echocardiography (TEE) with plaque ≥ 4 mm in thickness distal to the supposed embolized artery (judgement of the investigator). Contraindication to clopidogrel, aspirin, and oral anticoagulants

Sites / Locations

  • National Stroke Research Institute-Austin Health
  • Bichat Hospital Head of Neurology Department

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Clopidogrel-aspirin

Warfarin

Arm Description

Clopidogrel-aspirin

Warfarin

Outcomes

Primary Outcome Measures

New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death
New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death

Secondary Outcome Measures

Recurrent brain infarction
Recurrent brain infarction
brain infarction and transient ischemic attack (TIA)
brain infarction and transient ischemic attack (TIA)
new vascular events and revascularization procedure
new vascular events and revascularization procedure
vascular death
vascular death
death from all causes
death from all causes
combination of primary end-point and TIA
combination of primary end-point and TIA
revascularization procedures
revascularization procedures
urgent rehospitalization for ischemic
urgent rehospitalization for ischemic

Full Information

First Posted
October 6, 2005
Last Updated
July 6, 2012
Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
National Health and Medical Research Council, Australia, Sanofi, Bristol-Myers Squibb
search

1. Study Identification

Unique Protocol Identification Number
NCT00235248
Brief Title
Aortic Arch Related Cerebral Hazard Trial (ARCH)
Acronym
ARCH
Official Title
Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery
Study Type
Interventional

2. Study Status

Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
February 2002 (undefined)
Primary Completion Date
December 2010 (Actual)
Study Completion Date
July 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
Collaborators
National Health and Medical Research Council, Australia, Sanofi, Bristol-Myers Squibb

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The ARCH is a controlled trial with a sequential design and with a prospective, randomized, open-label, blinded-endpoint (PROBE) methodology. The objective is to compare the efficacy and tolerance (net benefit) of two antithrombotic strategies in patients with atherothrombosis of the aortic arch and a recent (less than 6 months) cerebral or peripheral embolic event. Hypothesis: The association of clopidogrel 75 mg/d plus aspirin 75 mg/d is 25% more effective than an oral anticoagulant (target International Normalized Ratio [INR] 2 to 3) in preventing brain infarction, brain hemorrhage, myocardial infarction, peripheral embolism, and vascular death.
Detailed Description
Patients with Transient Ischemic attack or brain infarction of unknown cause (no ipsilateral internal carotid artery origin stenosis greater than 70%, no ipsilateral severe intracranial stenosis of an artery supplying the infarcted area, no definite cardiac source of embolism) in the preceding 6 months and atherosclerotic plaques. ≥ 4 mm in the aortic arch, or patients with a peripheral event (e.g. renal infarct) in the preceding 6 months and plaque ≥ 4 mm in the thoracic aorta above the origin of the embolized artery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Brain Infarction, Transient Ischemic Attack, Embolism
Keywords
TIA/Brain infarct, and plaque>4mm in the aortic arch, Or peripheral embolism, and plaque>4 mm in the thoracic aorta

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
350 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Clopidogrel-aspirin
Arm Type
Experimental
Arm Description
Clopidogrel-aspirin
Arm Title
Warfarin
Arm Type
Active Comparator
Arm Description
Warfarin
Intervention Type
Drug
Intervention Name(s)
Warfarin
Intervention Description
Warfarin
Intervention Type
Drug
Intervention Name(s)
Clopidogrel-aspirin
Intervention Description
Clopidogrel-aspirin
Primary Outcome Measure Information:
Title
New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death
Description
New vascular events assessed every 4 months including stroke, myocardial infarction (MI), peripheral events, and vascular death
Time Frame
every 4 months
Secondary Outcome Measure Information:
Title
Recurrent brain infarction
Description
Recurrent brain infarction
Time Frame
during the trial
Title
brain infarction and transient ischemic attack (TIA)
Description
brain infarction and transient ischemic attack (TIA)
Time Frame
during the studing
Title
new vascular events and revascularization procedure
Description
new vascular events and revascularization procedure
Time Frame
during the trial
Title
vascular death
Description
vascular death
Time Frame
during the trial
Title
death from all causes
Description
death from all causes
Time Frame
during the trial
Title
combination of primary end-point and TIA
Description
combination of primary end-point and TIA
Time Frame
during the trial
Title
revascularization procedures
Description
revascularization procedures
Time Frame
during the trial
Title
urgent rehospitalization for ischemic
Description
urgent rehospitalization for ischemic
Time Frame
during the trial

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients of both sexes aged ≥ 18 years with the following 4 inclusion criteria: One of the 3 following ischemic events in the preceding 6 months: Transient ischemic attack (TIA) Non-disabling brain infarcts: Inclusion within 6 months after onset Duration of symptoms and signs greater than 24 hours Neurological signs at the time of randomization with a Rankin Scale grade 3 or less With normal computed tomography (CT) scan or CT scan showing a brain infarct (even hemorrhagic infarct) Peripheral embolism Atherosclerotic plaque in the thoracic aorta is defined as wall thickness ≥ 4 mm where the protruding material is the largest, measured at transesophageal echocardiography with multiplane transducer or a plaque less than 4 mm but with mobile component. Informed consent signed Life expectancy > 3 years Exclusion Criteria: Other causes of embolism: Cardiac: endocarditis, atrial fibrillation, intra-cardiac thrombus, valvular prosthesis, rheumatic valvulopathy, left ventricular aneurysm, or ejection fraction less than 25% Atherosclerotic stenosis ipsilateral to the embolic territory: internal carotid artery stenosis greater than 70%, or severe (judgment of the investigator) intracranial stenosis, or scheduled carotid endarterectomy (in that case inclusion is possible 30 days after the procedure) Uncommon causes: dissection, vasculitis, procoagulant state, or sickle cell disease Other exclusion criteria: Intercurrent illness with life expectancy less than 36 months Pregnancy and non-menopausal women Unwillingness to participate Poor medication compliance expected Toxicomania Absolute indication for anticoagulant therapy (e.g. atrial fibrillation, intracardiac thrombus, prosthetic valve) Scheduled for carotid endarterectomy (randomization is possible 30 days after endarterectomy) CT scan with an intracranial lesion other than brain infarction (space occupying mass, intracranial hemorrhage) Transesophageal echocardiography (TEE) with plaque ≥ 4 mm in thickness distal to the supposed embolized artery (judgement of the investigator). Contraindication to clopidogrel, aspirin, and oral anticoagulants
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pierre Amarenco, Pr, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Stroke Research Institute-Austin Health
City
Heidelberg Heights
ZIP/Postal Code
Vic 3081
Country
Australia
Facility Name
Bichat Hospital Head of Neurology Department
City
Paris
ZIP/Postal Code
75018
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
24699050
Citation
Amarenco P, Davis S, Jones EF, Cohen AA, Heiss WD, Kaste M, Laouenan C, Young D, Macleod M, Donnan GA; Aortic Arch Related Cerebral Hazard Trial Investigators. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke. 2014 May;45(5):1248-57. doi: 10.1161/STROKEAHA.113.004251. Epub 2014 Apr 3.
Results Reference
derived

Learn more about this trial

Aortic Arch Related Cerebral Hazard Trial (ARCH)

We'll reach out to this number within 24 hrs